Cancers 2019, 11, 1885; doi:10.3390/cancers11121885 www.mdpi.com/journal/cancers

Review

Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy

Heidi Espedal 1,2,*, Tina Fonnes 3,4, Kristine E. Fasmer 1,2, Camilla Krakstad 3,4 and Ingrid S. Haldorsen 1,2,*

1 Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway; kristine.eldevik.fasmer@helse-bergen.no
2 Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, 5021 Bergen, Norway
3 Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway; tina.fonnes@uib.no (T.F.); camilla.krakstad@med.uib.no (C.K.)
4 Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway
* Correspondence: heidi.espedal@uib.no (H.E.); ingfrid.haldorsen@uib.no (I.S.H.)

Received: 30 October 2019; Accepted: 25 November 2019; Published: 27 November 2019

Abstract: Endometrial cancer is the most common gynecologic malignancy in industrialized countries. Most patients are cured by surgery; however, about 15% of the patients develop recurrence with limited treatment options. Patient-derived tumor xenograft (PDX) mouse models represent useful tools for preclinical evaluation of new therapies and biomarker identification. Preclinical imaging by magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT), single-photon emission computed tomography (SPECT) and optical imaging during disease progression enables visualization and quantification of functional tumor characteristics, which may serve as imaging biomarkers guiding targeted therapies. A critical question, however, is whether the in vivo model systems mimic the disease setting in patients to such an extent that the imaging biomarkers may be translatable to the clinic. The primary objective of this review is to give an overview of current and novel preclinical imaging methods relevant for endometrial cancer animal models. Furthermore, we highlight how these advanced imaging methods depict pathogenic mechanisms important for tumor progression that represent potential targets for treatment in endometrial cancer.

Keywords: preclinical imaging; imaging biomarkers; PDX models; mouse models; gynecological cancer; endometrial cancer; positron emission tomography; magnetic resonance imaging; computed tomography; optical imaging

1. Introduction

Endometrial cancer (EC) is the most common gynecologic malignancy in industrialized countries and the incidence is increasing [1,2]. Most patients present with early-stage disease and are cured by surgery; however, about 15% develop recurrence with limited treatment options and poor survival [3,4]. Although the identification of different genetic alterations has defined specific molecular subtypes with potential for more individualized therapy in EC, the clinical treatment mostly remains the same across molecular subtypes [4,5].

New, promising therapeutics based on preclinical models frequently fail to produce similar effects in clinical trials. This may be related to poor preclinical model systems such as immortalized cell lines implanted subcutaneously in mice, thus lacking metastatic potential and immediate relevance for the
human setting. However, during the last decade preclinical cancer models have advanced with the introduction of orthotopic models (tumor cells implanted in the organ of origin) and patient-derived tumor xenograft (PDX) models, both putatively more translatable and transferable to the clinic. Orthotopic PDX models have shown to mimic various human cancers in terms of histopathologic characteristics, genetic- and molecular alterations, metastatic potential and therapeutic response [6]. Animal models for the most common types of gynecologic cancers have been developed, including PDX of endometrial, cervical and ovarian cancer [7–9].

Monitoring intraabdominal gynecologic tumor growth is challenging and requires an advanced imaging system. Traditionally, it required sacrificing a large number of animals for various ex vivo assays and endpoint measurement of tumor size. These measurements derived from the same time point (at sacrifice) inherently provide only static tumor information not capturing the dynamically changing and interactive cascade of signaling events that induce tumor progression. Additionally, during therapeutic intervention some molecularly targeted drugs may yield effect without reducing the tumor volume [10] and this effect will consequently not be detected using this approach. Importantly, robust and valid imaging biomarkers for early prediction of treatment response prior to detectable tumor size reduction, may open the avenue for early tailoring of more individualized treatment strategies in cancer.

The use of small-animal imaging in cancer research has increased over the last decade, especially as the development of non-invasive advanced functional imaging techniques has allowed for in vivo longitudinal monitoring of tumor growth, metastatic spread and therapeutic response. Preclinical imaging therefore represents a useful tool for unravelling new imaging biomarkers for prediction and evaluation of treatment response that eventually can be translated into the clinic [11]. Our research group was, to our knowledge, the first to present a multimodal imaging set-up, similar to that routinely employed at primary diagnostic work-up in the clinic, to monitor tumor growth in an orthotopic model of EC [12]. This review will give an overview of available preclinical imaging modalities relevant for gynecological cancers, in particular focusing on EC. Furthermore, we will highlight novel possibilities for refined tumor characterization by emerging new functional imaging techniques and discuss some of the challenges with preclinical imaging in EC.

2. Literature Search

The PubMed/Medline and Web of Science databases were searched for articles published up to September 2019 with filtering for animal studies using the following terms and combinations thereof: “endometrial cancer/carcinoma” or “uterine cancer” in combination with “imaging”, “magnetic resonance imaging”, “positron emission tomography”, “single photon emission computed tomography” “computed tomography”, “ultrasound”, “bioluminescence” and “fluorescence”. In addition, we also searched the reference lists of selected studies and authors to identify additional relevant articles. All studies recognized were assessed for relevance by checking the title and abstract. All irrelevant articles, studies without access to the full text of the publication, non-English publications, letters and proceedings were excluded.

3. Imaging in Endometrial Cancer

Imaging plays a central role in the management of EC patients. Although EC is formally surgically staged according to the International Federation of Gynaecology and Obstetrics (FIGO) staging system [13], preoperative imaging findings guide primary surgical treatment and are especially useful to stratify high-risk patients for lymphadenectomy, which is a major clinical challenge [14]. Although guidelines for state-of-the-art preoperative imaging in EC exist [15], differences in access to advanced imaging facilities and dissimilar local preferences lead to variable practices across centers. In humans, transvaginal ultrasound and/or magnetic resonance imaging (MRI) is typically performed preoperatively to assess local tumor extent. Computed tomography (CT) alone or CT combined with positron emission tomography (PET-CT) are useful to assess both abdominal spread
to pelvic- and paraaortic lymph nodes as well as distant spread [16]. For EC animal models MRI, PET-CT, CT and single-photon emission computed tomography (SPECT) have been used to depict and monitor tumor growth. Furthermore, these imaging methods enable non-invasive evaluation and quantification of treatment efficacy using novel therapies and depict imaging markers that are closely linked to treatment response. Monitoring of preclinical EC tumor growth using ultrasound could potentially also represent a valuable adjunct to these imaging modalities; however, we are not aware of any preclinical EC studies using this method. Optical imaging using fluorescence can be used to detect sentinel lymph nodes (SLN) in EC with high accuracy [17–20] and optical imaging using fluorescence and bioluminescence has been widely used as an additional tool in preclinical EC studies.

3.1. MRI

MRI is a highly versatile modality with standard sequences yielding high soft-tissue resolution providing detailed information on anatomy, and advanced imaging techniques allow depiction of functional and microstructural properties of the tissue. Diffusion-weighted (DW)-MRI is a functional imaging method depicting random diffusion of water molecules that reflects microstructural tissue characteristics. Typically, malignant tumors exhibit higher cellular density which putatively induces restricted water diffusion; thus, malignant tumors are often distinguished from normal tissue by its restricted diffusion. The DW images using different diffusion weighting (b-values) are used to generate apparent diffusion coefficient (ADC) maps on which the diffusion coefficient of the tissue can be measured. Interestingly, changes in tumor ADC value, with normalization towards non-restricted diffusion during treatment, have been linked to a favorable treatment response [21]. Dynamic contrast-enhanced (DCE)-MRI is a different functional imaging method that depicts microvascular features and yields imaging parameters reflecting tissue perfusion and permeability. For EC diagnosis, conventional pelvic MRI is an excellent method to assess myometrial- and cervical stroma invasion [16], and both DW- and DCE-MRI are considered promising supplementary MR sequences in EC for the prediction of advanced stage and an aggressive clinical phenotype [22,23].

We have successfully imaged an orthotopic mouse model of EC using MRI, illustrating the feasibility of anatomical MR sequences (T1 and T2-weighted) to depict tumor growth in the uterine horns in mice [12]. Interestingly, the hyperintense tumor signal on T2-weighted series and the hypointensity of the tumor (relative to the surrounding myometrium) on contrast-enhanced (CE) T1-weighted series resemble that observed in human EC (Figure 1). Furthermore, the tumors in mice also exhibit restricted diffusion on DW-MRI with hyperintensity on high b-value images and corresponding low ADC value on the ADC map, being similar to that characteristically observed in humans (Figure 1, Table 1) [12]. For further insight into characteristic imaging findings at conventional imaging and novel promising imaging methods in human EC, we direct the readers to our recent review [16].
Figure 1. Axial magnetic resonance (MR) images depicting tumor (arrows) in an orthotopic endometrial cancer (EC) mouse model (Ishikawa cells) (A–D), and corresponding axial MRI images visualizing a uterine tumor (arrows) in an 87-year-old woman with EC (grade 2 endometroid, FIGO stage IIIC1; same patient as in Figure 2) (E–H). (A,E) T2-weighted images depict hyperintense tumors and (B,F) T1-weighted contrast-enhanced images (T1+c) depict moderately enhancing uterine tumors. (C,G) Both the preclinical- and human tumors exhibit restricted diffusion with hyperintensity on high b-value diffusion-weighted imaging (DWI) and (D,H) corresponding hypointensity on the apparent diffusion coefficient (ADC) maps. Images A–D are reproduced under the open access CC BY license from a previous publication [12].

The loss of the phosphatase and tensin homolog (PTEN) is a frequent genetic aberration in EC [5], and PTEN loss leads to alterations in the oncogenic PI3K signaling pathway and impaired homologous recombination (HR) repair of DNA breaks [24]. In a treatment study, T2-weighted MRI was used in a genetic mouse model of PTEN-deficient EC to show reduced tumor volume as a result of a synergistic effect to combined treatment with PI3K- (BKM120) and poly (ADP-ribose) polymerase (PARP) inhibitors (Olaparib) (Table 1) [25]. Similarly, T2-weighted MRI was used to show the tumor size dependency on the mammalian target of rapamycin (mTOR) inhibitor rapamycin in a mouse genetic model where EC developed after deletion of the tumor suppressor liver kinase 1B (Lkb1), a negative regulator of the AMP-activated protein kinase (AMPK)-mTOR pathway (Table 1) [26].
Figure 2. FDG PET-CT depicting an FDG-avid tumor in an orthotopic patient-derived xenograft (PDX) model of EC (grade 3 endometrioid) (A–C), and in an 87-year-old woman with EC (grade 2 endometroid, FIGO stage IIIC1; same patient as in Figure 1) (D–F). (A) In the mouse model, axial non-contrast CT imaging depicts a large tumor (t) (arrows) in the abdomen whereas (B) axial (C) and coronal FDG PET-CT display increased FDG uptake in the periphery of the tumor (arrows) and a central necrotic core (n). (D) In the patient, diagnostic contrast-enhanced axial CT image depicts a slightly enhancing primary tumor (arrows) and (E) axial and (F) coronal FDG PET-CT depict an FDG-avid primary uterine tumor (arrow) and a metastatic parailiac lymph node (arrow). Physiologic FDG uptake in the heart (h), liver, kidneys, renal pelvis and intestines and urinary FDG excretion to the bladder (b) is visible.

3.2. PET

PET imaging in oncology is most often performed using the $^{18}$F-labeled glucose, fluorodeoxyglucose (FDG). Malignant cells are metabolically characterized by elevated energy demands and will normally have an increased uptake of glucose. Cancers will therefore typically exhibit high uptake of FDG generating contrast in PET images. PET-CT can detect lymph node metastases in EC with high accuracy, thus preoperative FDG-PET imaging is often recommended in high-risk EC [27,28]. In addition to elevated FDG uptake in metastatic lymph nodes, primary EC are also typically highly FDG avid [27]. Increased FDG uptake in an orthotopic tumor model from both Ishikawa cells and from human endometrioid grade 3 EC (PDX) has been demonstrated by our group using small-animal PET (Table 1) [12], and representative images illustrating the similar PET-CT findings observed in the PDX model and in human EC (endometroid grade 2, FIGO IIIIC1) is shown in Figure 2.

In a preclinical EC treatment study, it was recently shown that maximum standardized uptake values (SUVmax) decreased in lung metastases established from EC cell lines KLA and AN3CA by inhibiting the PI3K-pathway using ellagic acid (Table 1) [29].
3.3. CT

CT of the thorax, abdomen and pelvis is widely used to detect lymph node metastases and distant spread in EC patients [16]. In preclinical studies, CT has been used to detect both local and advanced disease. In an estrogen-controlled orthotopic model of EC using contrast-enhanced CT (CE-CT), image-derived tumor volume was found to be positively correlated to tumor net weight at necroscopy (Table 1) [7]. CT was also used to detect lung metastases in a genetic mouse model where conditional inactivation of a downstream target of the transforming growth factor β (TGFβ) receptor, activin-like kinase 5 (Alk5), led to EC (Table 1) [30]. Furthermore, CT-assessed regression of lung metastases after ovariectomy indicated that the tumors were hormone-dependent [30].

3.4. SPECT

SPECT is a nuclear medicine imaging technique based on the detection of gamma rays such as technetium-99 m (99mTc) and iodine-123 (123I). Clinically, SPECT-CT with 99mTc nanocolloid/tin colloid has been used preoperatively to identify SLN to stratify for lymphadenectomy in low-risk EC patients [19,31]. In preclinical EC models, SPECT has been used to monitor treatment efficacy of two different strains of oncolytic viruses (Copenhagen and Wyeth vaccinia virus) in subcutaneous AN3CA and ARK-2 cell-line xenografts (Table 1) [32].

3.5. Optical Imaging

Optical imaging, which can be performed using bioluminescence (BLI) or fluorescence (FLI) imaging techniques, is an excellent tool for visualization of tumor growth, metastases and treatment effects in preclinical models. BLI requires transfection with luciferase-expressing reporter genes, and as normal cells do not express luciferase, BLI provides excellent sensitivity for detecting tumor cells and high signal-to-noise ratio [33,34]. Unfortunately, this also causes BLI to be ineligible for imaging of PDX models, where genetic alteration of cells is unwarranted. In preclinical EC, BLI imaging has been employed longitudinally to monitor tumor growth and metastatic spread [12,35] and to demonstrate estrogen dependent tumor growth in orthotopic mouse models (Table 1) [7]. A representative BLI image of a mouse orthotopically implanted with luciferase-expressing Hec1B tumor cells is shown together with the corresponding necroscopy finding in Figure 3. In addition to visualizing tumor growth, BLI can be used to monitor the activity of specific signaling pathways, including the identification of significantly reduced activity in the NF-κB pathway following treatment with the heat shock protein inhibitor NVP-AUY922 [36] (Table 1).

![Figure 3. Bioluminescence imaging of an orthotopic EC mouse model. (A) Bioluminescence image and (B) post-mortem examination of a female NSG mouse ten weeks post orthotopic implantation with luciferase-expressing Hec1B cells. (D) Post-mortem examination revealed a primary uterine tumor and (C) liver metastases corresponding to the bioluminescence signal.](image-url)
Fluorescent imaging (FLI) techniques are increasingly applied in preclinical research. Red fluorescence generated by low doses of 5-aminolevulinic acid was recently demonstrated to allow visualization of EC xenografts following ultrasound microbubble- and polyethyleneimine-mediated knock-down of the enzyme ferrocheletase [37]. Furthermore, FLI using green fluorescent protein has been employed to study the anti-tumor effect of the mTOR inhibitor rapamycin in EC models with different PTEN expression levels. Rapamycin was found to more effectively inhibit tumor growth in PTEN-negative EC tumors compared to PTEN-positive [38]. Similar to SLN-mapping using fluorescent dyes in humans, fluorescence-guided resection of primary tumor and metastatic lymph nodes in an orthotopic rabbit model of EC yielded overall good sensitivity and specificity overall [39].

Table 1. Preclinical imaging of endometrial cancer.

| Imaging Modality/Sequence | Study Purpose | Imaging Characteristics | Animal Model | Ref |
|---------------------------|---------------|-------------------------|--------------|-----|
| MRI T1, T1+C, T2, DW, ADC | Present preclinical imaging findings using multiple imaging techniques | Tumor can be delineated using anatomic sequences and exhibits restricted diffusion with low ADC-values | Ishikawa cells, orthotopic, NSG mice | [12] |
| T2                        | Explore therapeutic effect of combined PISK (BKM120) and PARP-Inhibitor (Olaparib) treatment | Tumor volume decreased after combined treatment (synergistic effect) | Genetic mouse model (PTEN/Lkb1-deficient) | [25] |
| T2                        | Present a novel genetic mouse model | Tumor volume dependent on rapamycin treatment (mTOR inhibitor). | Genetic mouse model (Lkb1-deficient) | [26] |
| CT (CE-CT)                | Present an estrogen-controllable mouse model with image-guided monitoring of tumor-growth | Correlation between CT-assessed tumor volume and tumor weight at necropsy | Ishikawa cells, orthotopic, estrogen-controllable, athymic nude mice | [7] |
| CT                        | Present a novel genetic mouse model | Detection of lung metastases and regression of metastases post-therapy (ovariectomy) | Genetic mouse model, hormone dependent (AI susceptible) | [30] |
| PET FDG                   | Present preclinical imaging findings using multiple techniques | Growth of primary tumor and metastases can be detected | Ishikawa cells and PDX-model, orthotopic, NSG mice | [12] |
| FDG                       | Explore effect of PISK-inhibitor (elagic acid) | Decreased SUVmax in metastases (lung) after treatment | Cell lines KLE and ANICA injected iv. in BALB/c nude mice | [29] |
| SPECT (NIS reporter gene) Optical BLI | Explore effect of oncolytic therapy | Tumor volume decreased after therapy | Cell lines ANICA and ARK-2, subcutaneous athymic nude mice | [32] |
| CT                        | Generation and characterization of a mouse model | BLI signal increases over time. Metastatic growth detected | Hec1A cells, orthotopic, athymic nude mice | [35] |
| FLI                       | Present preclinical imaging findings using multiple techniques | Bli signal increases over time. Metastatic growth detected | Ishikawa cells, orthotopic, NSG mice | [12] |
| FLI                       | Present an estrogen-controllable mouse model with image-guided monitoring of tumor-growth | Bli signal increases in estrogen-treated mice | Ishikawa cells, orthotopic, athymic nude mice | [7] |
| FLI                       | Evaluate effect of Hsp90-inhibitor (NVP-AUY922) | NVP-AUY922 treatment reduces activity in the NF-κB pathway detected by BLI signal | Ishikawa cells, subcutaneous, (unknown mice strain) | [36] |
| FLI                       | Optimization of fluorescent signal | Low dose ALA permits detection of tumor by FLI following knockdown of FECH by ultrasound microbubbles and polyethyleneimine | HeLa cells, subcutaneous, BALB/c nude mice | [37] |
| FLI                       | Investigate mTOR treatment in tumors of different PTEN-status (+/−) | Decreased GFP signal in PTEN−/− compared to PTEN+ for rapamycin-treated tumors | HeLa (PTEN+) and Ishikawa (PTEN−) subcutaneous, BALB/c nude mice | [38] |
| FLI                       | Explore fluorescence-guided resection of tumor and metastases | Detection and surgical removal of fluorescent tumor tissue with high sensitivity and specificity | VX2 rabbit tumor cells, orthotopic, White New Zealand rabbits | [39] |

**Abbreviations:** ADC apparent diffusion coefficient, ALA 5-aminolevulinic acid, ALk5 activin-like kinase 5, BLI bioluminescent imaging, CE contrast-enhanced, CT computed tomography, DW diffusion-weighted, FDG fluorodeoxyglucose, FECH ferrochelatase, FLI fluorescence imaging, GFP green fluorescent protein, Hsp90 heat shock protein 90, iv. intravenous, Lkb1 liver kinase b1, MRI magnetic resonance imaging, mTOR mammalian target of rapamycin, MTV metabolic tumor volume, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells, NSG NOD scid gamma mouse, PARP poly (ADP-ribose) polymerase, PDX patient-derived xenograft, PET positron emission tomography, PTEN phosphatase and tensin homolog, SPECT single-photon emission computed tomography, SUV standardized uptake value.
4. Emerging Novel Imaging Techniques Relevant for Preclinical EC Models

Novel imaging methods and new tracers have the potential to yield clinically relevant cancer biomarkers. Monitoring tumor growth in animal models using these imaging methods represents an ideal research platform for testing and validation of cancer biomarkers prior to potential implementation in the clinic. We will highlight promising and novel imaging techniques potentially relevant for preclinical imaging of EC models using examples from breast and gynecologic cancers.

4.1. Radioligands for Visualization of Target-Specific Expression in EC

Targeted radioisotopes that bind to specific genetic alterations may identify subgroups of patients that are likely to respond to corresponding targeted therapies, and may therefore serve as an imaging method (using PET and SPECT) for treatment stratification in EC. Isotopes are summarized in Table 2.

Targeting of the human epidermal growth factor receptor-2 (HER2) is implemented in the treatment of HER2-positive breast cancer, but is less studied for treatment of EC. We have recently shown that high HER2 expression is associated with aggressive disease and poor survival in EC [41]. $^{89}$Zr-labeled pertuzumab ($^{89}$Zr-pertuzumab) has been used to detect HER2-positive breast cancer in small human cohorts [42,43] and to delineate tumors and show treatment effects from trastuzumab-entansine (T-DM1) in HER2-positive breast cancer xenografts [44]. Similarly, PET-CT with radiolabeled pertuzumab ($^{64}$Cu-NOTA-pertuzumab) was used for non-invasive detection and monitoring of HER2 tumor expression, enabling the detection of primary tumors and peritoneal metastases in both subcutaneous and orthotopic models of ovarian cancer [45].

Cancer antigen 125 (CA125) is an important biomarker in clinical use for ovarian cancer; however, CA125 has also been shown to predict lymph node metastases in EC [46]. A preclinical radiotracer using $^{89}$Zr labeled mAb-B43.13 ($^{89}$Zr-DFO-B43.13) to target CA125 expression by PET was recently developed and validated in OVCAR3 ovarian xenografts [47], and this approach seems highly relevant for future testing also in preclinical EC models.

It has been shown that tumor expression of epithelial membrane protein 2, EMP2 is associated with aggressive disease in EC, and that EMP2 represents a novel biomarker for EC development [48,49]. Using radiolabeled antibody fragments of EMP2, $^{64}$Cu-DOTA-EMP2, this tracer was able to detect tumor growth in a cell-line based Hec1a EC xenografts model in mice by PET [50].

The recently discovered G-protein coupled estrogen receptor (GPER) is expressed in tumors where estrogen- and progesterone receptors are downregulated, and is associated with poor survival in EC [51,52]. A $^{99m}$Tc-labeled GPER ligand for use with SPECT was recently developed and validated in EC Hec50 xenografts [53].

Table 2. Target-specific radiotracers relevant for endometrial cancer.

| Target/Modality | Clinical Relevance/Finding | Tracer | Preclinical Animal Model/Finding |
|-----------------|---------------------------|--------|---------------------------------|
| HER2–PET        | HER2 positivity predicts aggressive disease and poor outcome [41]. | $^{89}$Zr-pertuzumab | Uptake in human HER2+ breast cancer [42,43] and mouse HER2+ xenografts (BT-474) including evaluation of tumor size change after treatment with HER2-targeted antibody-drug conjugate (T-DM1) [44]. High specificity to HER2 expression and delineation of tumor and metastases in orthotopic and subcutaneous ovarian cancer xenografts [45]. High uptake and delineation of subcutaneous tumors of EMP2-overexpressing Hec1a-cells [50]. |
|                 |                           | $^{64}$Cu-NOTA-pertuzumab |                                  |
| EMP2–PET        | High EMP2 expression predicts aggressive disease [48,49]. | $^{64}$Cu-DOTA-EMP2 |                                  |
4.2. Oncologic PET Tracers Relevant for EC

A wide range of novel PET tracers are currently being developed with the aim of depicting relevant biological processes and molecular targets in oncology, but presently there is little experience with PET tracers beyond FDG in EC. We describe some of the more general radiotracers with potential relevance for patient stratification and treatment assessment in EC. A summary is given in Table 3.

\( ^{18}\)F-labeled thymidine (FLT), is a PET tracer used to depict tissue with actively proliferating cells. FLT is taken up and trapped intracellularly after phosphorylation by thymidine kinase 1 during the S-phase of the cell cycle. Although not yet tested clinically for EC, we have demonstrated the feasibility of FLT-PET to detect and monitor tumor growth in our EC mouse model [12]. For a number of different tumors including animal models of breast- and ovarian cancers, FLT-PET has been used to evaluate treatment response [54–60].

Unopposed estrogen stimulation is a central oncogenic mechanism driving the development of the majority of ECs (type I; endometrioid) [61]. Furthermore, receptor status in EC provides prognostic information, where loss of estrogen/ progesterone receptor (ER/PR) predicts lymph node metastases and poor survival [62]. Thus, PET using \( ^{18}\)F-fluoroestradiol (FES), to non-invasively depict and quantify whole-tumor expression of estrogen, has long been investigated for the clinical management of EC. Interestingly, Tsujikawa et al. found that the FDG-to-FES SUV ratio is related to tumor aggressiveness and that the more aggressive tumors depend less on estrogen and more on glucose metabolism. Furthermore, tumor FES-PET avidity correlated well with ER\(\alpha\) expression [63,64]. In a preclinical study, FES-PET was used to detect early treatment response to the endocrine therapy fulvestrant in an ER\(+\) breast cancer xenograft model (MCF7), a response which was not detectable by FDG-PET [65]. Similarly, in ER\(+\) breast xenografts (ZR-75-1) FES-PET could detect treatment response to fulvestrant, whereas FDG- and \( ^{18}\)F-fluoromisonidazole (FMISO; hypoxia tracer)-PET did not [66].

In general, hypoxia leads to a reduced response to chemo- and radiotherapy, and we have shown that imaging and tissue markers for hypoxia predict reduced survival in EC [67]. Therefore, detecting hypoxic tumors by preoperative functional imaging might have therapeutic consequences and improve risk-stratification. Several PET tracers for hypoxia have been developed and FMISO and \( ^{18}\)F-fluorooxymycin-arabinofuranoside (FAZA) represent two of the most common commercially available hypoxia tracers. Neither FAZA nor FMISO have been tested in preclinical or clinical EC, but both have shown promise for detection of hypoxic regions in cervical cancer [68,69] and in animal models of cervical and ovarian cancer [57,70,71].

4.3. Advanced MRI Sequences Relevant for EC

Advanced functional MRI sequences can be used to evaluate therapeutic response in cancer [21]. For preclinical gynecologic cancer models, but not yet for EC, DW- and DCE-MRI have been used to assess therapeutic cellular and vascular response following targeted therapies. DW-MRI was used to demonstrate treatment effects from perifosine, a PI3K-inhibitor, and the chemotherapeutic drug cisplatin in a genetic model of ovarian cancer [72]. Furthermore, DW- and DCE-MRI was used for the
non-invasive monitoring of treatment response during administration of the dual PI3K/mTOR-inhibitor BEZ235 in two different subcutaneous ovarian cell-line xenograft models [73]. Rofstad and colleagues have applied DCE-MRI to characterize hypoxia in the tumor microenvironment finding that low values of the contrast agent transfer constant (K\textsubscript{trans}) is associated with areas of hypoxia, resistance to radiotherapy and higher metastatic potential in cervical cancer models [74–76].

### 4.4. Advanced Image Analyses

One of the main advantages of the PET technology is the possibility to perform absolute quantification – also in small animals. Clinically, PET images are usually acquired by conventional static scanning, typically one hour post-injection for FDG-PET, and analyses are based on the semi-quantitative and variation-prone parameter SUV [77]. In contrast, dynamic PET depicts the distribution of the tracer in space and time from the time of injection, thus reflecting both the early uptake- and late distribution phase and the metabolism. Pharmacokinetic modeling from dynamic imaging can potentially yield functional tumor information beyond that represented by SUV and better characterize tumor heterogeneity and monitor therapeutic response [78,79]. Interestingly, dynamic FDG-PET using compartment modeling demonstrated treatment response from chemotherapeutics (doxorubicin, paclitaxel and carboplatin) in three different breast cancer xenografts in mice, a response which was not detectable using conventional SUV parameters [79].

**Table 3. Novel imaging techniques relevant for clinical and preclinical imaging in endometrial cancer.**

| Target                     | Imaging Modality/Sequence | Clinical Relevance                                                                                     | Clinical Findings                                                                                       | Preclinical Application and Findings                                                                 |
|----------------------------|--------------------------|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Tumor proliferation        | FLT-PET                  | Sustained proliferation is a hallmark of cancer, including EC.                                         | No human studies performed in EC.                                                                     | Growth of primary tumor and metastases can be detected and monitored longitudinally in EC mouse models [12]. |
|                            |                          |                                                                                        | FES-FDG ratio can predict grade in EC, FES-PET avidity is linked to ERα expression [63,64].          | FET can detect treatment response in breast- and ovarian cancer models [54–60].                        |
| Estrogen status            | FES-PET                  | Estrogen drives development of type | | | |
|                            |                          | 1/endometrial EC, receptor status can predict survival [61,62].                                        |                                                                                                       | Showed to predict early treatment response to fulvestrant in ER+ breast cancer xenografts [65,66].         |
| Tumor hypoxia             | FMISO-PET, FAZA-PET, DCE-MRI (K\textsubscript{trans}) | Hypoxia predicts poor survival in EC [67].                                                            | FMISO- and FAZA-PET depict hypoxic regions in cervical cancer [68,69].                                | FMISO- and FAZA-PET depict growth of subcutaneous ovarian xenografts and enable monitoring of treatment response (chemotherapy) [57]. Low tumor values of K\textsubscript{trans} is associated with hypoxia in cervical cancer models [74–76]. DHW (ADC value is negatively correlated to Ki67 proliferation index) to assess treatment response by PI3K-inhibitor perifosin and cisplatin in ovarian xenografts [72]. |
| Tumor heterogeneity and vascularity | DW- and DCE MRI | DW- and DCE-MRI are valuable supplements to conventional diagnostic MRI sequences [22,23]. | DCE-parameters (F\textsubscript{re}, K\textsubscript{trans} and V\textsubscript{e}) are lower in tumor than normal myometrium, tumor ADC is negatively correlated to tumor volume [23]. | Rate constants K\textsubscript{1} and K\textsubscript{2} (perfusion) was higher and K\textsubscript{3} was lower (metabolism) in breast cancer xenografts treated with chemotherapy; this response was not detectable by traditional SUV analyses [73]. |

**Abbreviations:** ADC apparent diffusion coefficient, DCE dynamic-contrast enhanced, DW diffusion-weighted, ER\textalpha estrogen receptor \textalpha, FAZA fluoroazomycin-arabinofuranoside, FDG fluorodeoxyglucose, FLT fluothymidine, FMISO fluoromisonidazole, K\textsubscript{trans} volume transfer constant, MRI magnetic resonance imaging, mTOR mammalian target of rapamycin, PET positron emission tomography, PI3K phosphoinositide 3-kinase, SUV standardized uptake value, V\textsubscript{e} extravascular extracellular space.
5. Imaging-Related Challenges in Preclinical Endometrial Cancer Models

Primary gynecologic cancers are localized in the small pelvis in close proximity to the bladder and the bowels; this often makes it challenging to distinguish tumor from surrounding, normal tissues. As many PET tracers are excreted through the urinary track to the bladder; spill-over from the bladder due to the partial volume effect (PVE) can affect the delineation of tracer avid tumor tissue adjacent to the bladder and sometimes mask the entire tumor, especially in orthotopic mouse models. Furthermore, physiologic FDG uptake in intestines and other abdominal organs can affect the tumor segmentation even when fasting the mice prior to imaging (to reduce intestinal FDG uptake). Similarly, FLT physiological uptake in proliferating tissues e.g., the intestines [12] and FMISO uptake by anaerobic fecal bacteria [80] can complicate tumor segmentation.

For absolute quantification of dynamic PET or DCE-MRI images, the arterial input function (AIF) is needed. To acquire AIF, the gold standard requires manual blood sampling at several time-points after tracer/contrast agent injection. As the blood volume in small animals is very small (estimated 55–70 mL/kg body weight [81]), the method is technically challenging, subject to considerable variation and does not allow for longitudinal studies. Several alternatives to derive the AIF exists, including a pump-driven arteriovenous shunt connected to a coincidence counter (e.g., Twilite by Swisstrace), a microfluidic chip blood-counting system [82] or indirect estimates based on the dynamic images (image-derived input function, IDIF) or using a population-based input function (with or without a blood sample for scaling). Which method that yields the most accurate quantification is however, debated. Furthermore, the technical ease of the imaging procedure and the accumulated burden for the animals undergoing sequential examinations are critical, if these practical interventional methods are to be feasible for a broader use.

6. Conclusions

Detection and monitoring of tumor growth in preclinical EC models by using clinical imaging methods such as CT, MRI, SPECT and PET is feasible. These dedicated small-animal imaging technologies enable the identification of imaging biomarkers reflecting functional, microstructural and metabolic tumor features relevant for EC phenotype. The majority of preclinical studies exploring new targeted therapies with potential for personalizing EC treatment, still rely on endpoint volumetric measurements of tumor size. The therapeutic effect of molecularly targeted drugs not having an immediate effect on tumor size may consequently be overlooked. However, novel functional imaging techniques and new tracers enable quantification and depiction of molecularly targetable pathogenic mechanisms, yielding information beyond what has previously been obtainable. However, the development of relevant target-specific imaging biomarkers in EC is still in its infancy, and new imaging techniques and tracers are likely to be developed in the near future. Furthermore, all promising imaging techniques will require careful validation and clinical testing prior to potential translation into the clinic. Importantly, imaging biomarkers identified by preclinical models with subsequent validation in clinical patient series, are likely to play a central role in future developments of new targeted treatment strategies in gynecologic cancer.

Author Contributions: Conceptualization: H.E. and I.S.H.; literature search: H.E. and T.F.; investigation: H.E. and T.F.; visualization: H.E, T.F and K.E.F.; writing—original draft preparation: H.E, writing, review and editing, all authors.; funding acquisition: C.K. and I.S.H.

Funding: This project was funded by the Trond Mohn Foundation (BFS2018TMT06), the Western Norway Regional Health Authority (Grant #912263), the Norwegian Cancer Society (Grant #190202) and the Norwegian Research Council (Grant #273280).

Acknowledgments: Thanks to Trond Mohn Foundation and the core facilities for imaging at University of Bergen; Molecular Imaging Center (MIC).

Conflicts of Interest: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Compliance with ethical standards: Experimental procedures on animals were approved by the national animal research authorities (Mattilsynet, application ID 6080 and 6710). Diagnostic images in Figures 1 and 2 are from a consenting patient (IRB approval: 2015/2333/REK vest).

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. *CA Cancer J. Clin.* 2018, 68, 7–30. [CrossRef]
2. Zhang, Y.; Liu, H.; Yang, S.; Zhang, J.; Qian, L.; Chen, X. Overweight, obesity and endometrial cancer risk: Results from a systematic review and meta-analysis. *Int. J. Biol. Markers* 2014, 29, e21–e29. [CrossRef]
3. Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.; Siegel, R.L. Cancer treatment and survivorship statistics, 2019. *CA Cancer J. Clin.* 2019, 69, 363–385. [CrossRef]
4. Matei, D.; Filiaci, V.; Randall, M.E.; Mutch, D.; Steinhoff, M.M.; DiSilvestro, P.A.; Moxley, K.M.; Kim, Y.M.; Powell, M.A.; O’Malley, D.M.; et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. *N. Engl. J. Med.* 2019, 380, 2317–2326. [CrossRef]
5. Cancer Genome Atlas Research Network; Kandoth, C.; Schultz, N.; Cherniack, A.D.; Akbani, R.; Liu, Y.; Shen, H.; Robertson, A.G.; Pashtan, I.; Shen, R.; et al. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013, 497, 67–73. [CrossRef]
6. Cook, N.; Jodrell, D.I.; Tuveson, D.A. Predictive in vivo animal models and translation to clinical trials. *Drug Discov. Today* 2012, 17, 253–260. [CrossRef]
7. Konings, G.F.; Saarinen, N.; Delvoux, B.; Kooreman, L.; Koskimies, P.; Krakstad, C.; Fasmer, K.E.; Haldorsen, I.S.; Zaffagnini, A.; Hakkinen, M.R.; et al. Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure. *Int. J. Mol. Sci.* 2018, 19, 2547. [CrossRef]
8. Moiola, C.P.; Lopez-Gil, C.; Cabrera, S.; Garcia, A.; Van Nyen, T.; Annibali, D.; Fonnes, T.; Vidal, A.; Villanueva, A.; Matias-Guiu, X.; et al. Patient-Derived Xenograft Models for Endometrial Cancer Research. *Int. J. Mol. Sci.* 2018, 19, 2431. [CrossRef]
19. Tanaka, T.; Terai, Y.; Fujiwara, S.; Tanaka, Y.; Sasaki, H.; Tsunetoh, S.; Yamamoto, K.; Yamada, T.; Ohmichi, M. The detection of sentinel lymph nodes in laparoscopic surgery can eliminate systemic lymphadenectomy for patients with early stage endometrial cancer. Int. J. Clin. Oncol. 2018, 23, 305–313. [CrossRef]

20. Bedińska, M.; Szewczyk, G.; Klepacka, T.; Sachadel, K.; Maciejewski, T.; Szukiewicz, D.; Fijałkowska, A. Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: Restrictions of the method. Arch. Gynecol. Obstet. 2019, 299, 1373–1384. [CrossRef]

21. Galban, C.J.; Hoff, B.A.; Cheneverut, T.L.; Ross, B.D. Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed. 2017, 30. [CrossRef]

22. Haldorsen, I.S.; Gruner, R.; Husby, J.A.; Magnussen, I.J.; Werner, H.M.; Salvesen, O.O.; Bjorge, L.; Stefansson, I.; Akslen, L.A.; Trovik, J.; et al. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. Eur. Radiol. 2013, 23, 2916–2925. [CrossRef]

23. Joshi, A.K.; Reitan, B.C.; Trovik, J.; Krakstad, C.; et al. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiol. 2018, 59, 1010–1017. [CrossRef]

24. Xu, W.; Yang, Z.; Zhou, S.F.; Lu, N. Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. Drug Des. Dev. Ther. 2014, 8, 1745–1751. [CrossRef]

25. Bian, X.; Gao, J.; Luo, F.; Rui, C.; Zheng, T.; Wang, D.; Wang, Y.; Roberts, T.M.; Liu, P.; Zhao, J.J.; et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 2018, 37, 341–351. [CrossRef]

26. Contreras, C.M.; Akbay, E.A.; Gallardo, T.D.; Haynie, J.M.; Sharma, S.; Tagao, O.; Bardeesy, N.; Takahashi, M.; Settleman, J.; Wong, K.K.; et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis. Models Mech. 2010, 3, 181–193. [CrossRef]

27. Husby, J.A.; Reitan, B.C.; Biermann, M.; Trovik, J.; Bjorge, L.; Magnussen, I.J.; Salvesen, O.O.; Salvesen, H.B.; Haldorsen, I.S. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients. J. Nucl. Med. 2015, 56, 1191–1198. [CrossRef]

28. Bollineni, V.R.; Ytre-Hauge, S.; Bollineni-Balabay, O.; Salvesen, H.B.; Haldorsen, I.S. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature. J. Nucl. Med. 2016, 57, 879–885. [CrossRef]

29. Wang, Y.; Ren, F.; Li, B.; Song, Z.; Chen, P.; Ouyang, L. Ellagic acid exerts antitumor effects via the PI3K signaling pathway in endometrial cancer. J. Cancer 2019, 10, 3303–3314. [CrossRef]

30. Monsivais, D.; Peng, J.; Kang, Y.; Matzuk, M.M. Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma. Proc. Natl. Acad. Sci. USA 2019, 116, 3883–3892. [CrossRef]

31. Holloway, R.W.; Abu-Rustum, N.R.; Backes, F.J.; Boggess, J.F.; Gotlieb, W.H.; Jeffrey Lowery, W.; Rossi, E.C.; Tanner, E.J.; Wolsky, R.J. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol. Oncol. 2017, 146, 405–415. [CrossRef]

32. Liu, Y.P.; Wang, J.; Avanzato, V.A.; Bakkum-Gamez, J.N.; Russell, S.J.; Bell, J.C.; Peng, K.W. Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol. Oncol. 2014, 132, 722–729. [CrossRef]

33. Kocher, B.; Piwnica-Worms, D. Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo. Cancer Discov. 2013, 3, 616–629. [CrossRef]

34. Wang, Y.; Tseng, J.C.; Sun, Y.; Beck, A.H.; Kung, A.L. Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer. Cold. Spring Harb. Protoc. 2015, 2015, 135–144. [CrossRef]

35. Cabrera, S.; Llaurado, M.; Castellvi, J.; Fernandez, Y.; Alameda, F.; Colas, E.; Ruiz, A.; Dell, A.; Schwartz, S., Jr.; Carreras, R.; et al. Generation and characterization of orthotopic murine models for endometrial cancer. Clin. Exp. Metastasis 2012, 29, 217–227. [CrossRef]

36. Yeramian, A.; Garcia, V.; Bergada, L.; Domingo, M.; Santacana, M.; Valls, J.; Martinez-Alonso, M.; Carceller, J.A.; Cussac, A.L.; Dolcet, X.; et al. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-kappaB Pathway in Endometrial Cancer. Mol. Imaging Biol. 2016, 18, 545–556. [CrossRef]
Cancers 2019, 11, 1885

37. Zhang, X.; Chen, L.; Gao, L.; Gao, X.; Li, N.; Song, Y.; Huang, X.; Lin, S.; Wang, X. Comparative Study of the Effects of Ferrochelatase-siRNA Transfection Mediated by Ultrasound Microbubbles and Polylethyleneimine in Combination with Low-dose ALA to Enhance PpIX Accumulation in Human Endometrial Cancer Xenograft Nude Mice Models. *Photochem.Photobiol.* 2019, 95, 1045–1051. [CrossRef]

38. Fong, P.; Meng, L.R. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status. *Med. Sci. Monit. Basic Res.* 2014, 20, 146–152. [CrossRef]

39. Philp, L.; Chan, H.; Rouzbahman, M.; Overchuk, M.; Chen, J.; Zheng, G.; Bernardini, M.Q. Use of Porphysomes to detect primary tumour, lymph node metastases, intra-abdominal metastases and as a tool for image-guided lymphadenectomy: Proof of concept in endometrial cancer. *Theranostics* 2019, 9, 2727–2738. [CrossRef]

40. Cheng, H.; Liu, P.; Zhang, F.; Xu, E.; Symonds, L.; Ohlson, C.E.; Bronson, R.T.; Maira, S.M.; Di Tomaso, E.; Li, J.; et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. *Cancer Res.* 2014, 74, 15–23. [CrossRef]

41. Halle, M.K.; Tangen, I.L.; Berg, H.F.; Hoivik, E.A.; Mauland, K.K.; Kusonmano, K.; Berg, A.; Hurtado, A.; Kalland, K.H.; Oyan, A.M.; et al. HER2 expression patterns in paired primary and metastatic endometrial carcinoma lesions. *Br. J. Cancer* 2018, 118, 378–387. [CrossRef]

42. Ulaner, G.A.; Lyashchenko, S.K.; Riedl, C.; Ruan, S.; Zanzonico, P.B.; Lake, D.; Jhaveri, K.; Zeglis, B.; Lewis, J.S.; O’Donoghue, J.A. First-in-Human Fundamental Epidermal Growth Factor Receptor 2-Targeted Imaging Using (89)Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. *J. Nucl. Med.* 2018, 59, 900–906. [CrossRef]

43. Dehdashti, F.; Wu, N.; Bose, R.; Naughton, M.J.; Ma, C.X.; Marquez-Nostra, B.V.; Dieboldser, P.; Mpoy, C.; Rogers, B.E.; Lapi, S.E.; et al. Evaluation of [(89)Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. *Breast Cancer Res. Treat.* 2018, 169, 523–530. [CrossRef]

44. Massicano, A.V.F.; Lee, S.; Crenshaw, B.K.; Aweda, T.A.; El Sayed, R.; Super, I.; Bose, R.; Marquez-Nostra, B.V.; Lapi, S.E. Imaging of HER2 with [(89)Zr]pertuzumab in Response to T-DM1 Therapy. *Cancer Biother. Radiopharm.* 2019, 34, 209–217. [CrossRef]

45. Jiang, D.; Im, H.J.; Sun, H.; Valdovinos, H.F.; England, C.G.; Ehlerding, E.B.; Nickles, R.J.; Lee, D.S.; Cho, S.Y.; Huang, P.; et al. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. *Eur. J. Nucl. Med. Mol. Imaging* 2017, 44, 1296–1305. [CrossRef]

46. Jiang, T.; Huang, L.; Zhang, S. Preoperative serum CA125: A useful marker for surgical management of endometrial cancer. *BMC Cancer* 2015, 15, 396. [CrossRef]

47. Sharma, S.K.; Sevak, K.K.; Monette, S.; Carlin, S.D.; Knight, J.C.; Wuest, F.R.; Sala, E.; Zeglis, B.M.; Lewis, J.S. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis. *J. Nucl. Med.* 2016, 57, 771–776. [CrossRef]

48. Wadghara, M.; Natarajan, S.; Seligson, D.B.; Williams, C.J.; Hummer, A.J.; Hedvat, C.; Braun, J.; Soslowsky, R.A. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. *Cancer* 2006, 107, 90–98. [CrossRef]

49. Habeeb, O.; Goodglick, L.; Soslowsky, R.A.; Rao, R.G.; Gordon, L.K.; Schirripa, O.; Horvath, S.; Braun, J.; Seligson, D.B.; Wadghara, M. Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. *Cancer* 2010, 116, 4718–4726. [CrossRef]

50. Fu, M.; Brewer, S.; Olafsen, T.; Wu, A.M.; Gordon, L.K.; Said, J.; Braun, J.; Wadghara, M. Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. *Mol. Imaging Biol.* 2013, 15, 68–78. [CrossRef]

51. Smith, H.O.; Leslie, K.K.; Singh, M.; Qualls, C.R.; Revankar, C.M.; Joste, N.E.; Prossnitz, E.R. GPR30: A novel indicator of poor survival for endometrial carcinoma. *Am. J. Obstet. Gynecol.* 2007, 196, 386.e1–386.e11. [CrossRef]

52. Krakstad, C.; Trovik, J.; Wik, E.; Engelsen, I.B.; Werner, H.M.; Birkeland, E.; Raeder, M.B.; Oyan, A.M.; Stefansson, I.M.; Kalland, K.H.; et al. Loss of GPER identifies new targets for therapy among a subgroup of ERalpha-positive endometrial cancer patients with poor outcome. *Br. J. Cancer* 2012, 106, 1682–1688. [CrossRef]

53. Nayak, T.K.; Ramesh, C.; Hathaway, H.J.; Norenberg, J.P.; Arterburn, J.B.; Prossnitz, E.R. GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding. *Mol. Cancer Res.* 2014, 12, 1635–1643. [CrossRef]
54. Aide, N.; Kinross, K.; Cullinane, C.; Roselt, P.; Waldeck, K.; Neels, O.; Dorow, D.; McArthur, G.; Hicks, R.J. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J. Nucl. Med. 2010, 51, 1559–1564. [CrossRef]

55. Jensen, M.M.; Erichsen, K.D.; Bjorkling, F.; Madsen, J.; Jensen, P.B.; Sehested, M.; Hojgaard, L.; Kjaer, A. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. BMC Cancer 2013, 13, 168. [CrossRef]

56. Munk Jensen, M.; Erichsen, K.D.; Bjorkling, F.; Madsen, J.; Jensen, P.B.; Sehested, M.; Hojgaard, L.; Kjaer, A. Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET. PLoS ONE 2013, 8, e85126. [CrossRef]

57. Trencsenyi, G.; Marian, T.; Lajtos, I.; Krasznai, Z.; Balkay, L.; Emri, M.; Mikecz, P.; Goda, K.; Szaloki, G.; Juhasz, I.; et al. 18FDG, [18F]FLT, [18F]FAZA, and 11C-methionine are suitable tracers for the diagnosis and in vivo follow-up of the efficacy of chemotherapy by miniPET in both multidrug resistant and sensitive human gynecologic tumor xenografts. Biomed Res. Int. 2014, 2014, 787365. [CrossRef]

58. Perumal, M.; Stronach, E.A.; Gabra, H.; Aboagye, E.O. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3-deoxy-3-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer. Mol. Imaging Biol. 2012, 14, 753–761. [CrossRef]

59. Shah, C.; Miller, T.W.; Wyatt, S.K.; McKinley, E.T.; Olivares, M.G.; Sanchez, V.; Nolting, D.D.; Buck, J.R.; Zhao, P.; Ansari, M.S.; et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin. Cancer Res. 2009, 15, 4712–4721. [CrossRef]

60. Elmi, A.; Makvandi, M.; Weng, C.C.; Hou, C.; Clark, A.S.; Mach, R.H.; Mankoff, D.A. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [18F]FLT and [(18)F]ISO-1 PET/CT. Clin. Cancer Res. 2019, 25, 3063–3073. [CrossRef]

61. Salvesen, H.B.; Haldorsen, I.S.; Trovik, J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012, 13, e353–e361. [CrossRef]

62. Trovik, J.; Wik, E.; Werner, H.M.; Krakstad, C.; Helland, H.; Vandenput, I.; Njolstad, T.S.; Stefansson, I.M.; Marckiewicz, J.; Tingulstad, S.; et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur. J. Cancer 2013, 49, 3431–3441. [CrossRef]

63. Tsujikawa, T.; Yoshida, Y.; Kurokawa, T.; Kudo, T.; Fujibayashi, Y.; Kotsuji, F.; Okazawa, H. Functional oestrogen receptor alpha imaging in endometrial carcinoma using 16alpha-[(1)(8)F]fluoro-17beta-oestradiol PET. Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 37–45. [CrossRef]

64. Tsujikawa, T.; Yoshida, Y.; Kudo, T.; Kiyono, Y.; Kurokawa, T.; Kobayashi, M.; Tsuchida, T.; Fujibayashi, Y.; Kotsuji, F.; Okazawa, H. Functional images reflect aggressiveness of endometrial carcinoma: Estrogen receptor expression combined with 18F-FDG PET. J. Nucl. Med. 2009, 50, 1598–1604. [CrossRef]

65. Heidari, P.; Deng, F.; Esfahani, S.A.; Leece, A.K.; Shoup, T.M.; Vasdev, N.; Mahmood, U. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader. Clin. Cancer Res. 2015, 21, 1340–1347. [CrossRef]

66. He, S.; Wang, M.; Yang, Z.; Zhang, J.; Zhang, Y.; Luo, J.; Zhang, Y. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer. PLoS ONE 2016, 11, e0159916. [CrossRef]

67. Berg, A.; Fasmer, K.E.; Mauland, K.K.; Ytre-Hauge, S.; Hoivik, E.A.; Husby, J.A.; Tangen, I.L.; Trovik, J.; Halle, M.K.; Woie, K.; et al. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. Oncotarget 2016, 7, 6984–69856. [CrossRef]

68. Han, K.; Shek, T.; Vines, D.; Driscoll, B.; Fyles, A.; Jaffray, D.; Keller, H.; Metser, U.; Pintilie, M.; Xie, J.; et al. Measurement of Tumor Hypoxia in Patients With Locally Advanced Cervical Cancer Using Positron Emission Tomography with (18)F-Fluorazomycin Arabinoside. Int. J. Radiat. Oncol. Biol. Phys. 2018, 102, 1202–1209. [CrossRef]

69. Pinker, K.; Andrzejewski, P.; Baltzer, P.; Polanec, S.H.; Sturda, A.; Georg, D.; Helbich, T.H.; Karanikas, G.; Grimm, C.; Polterauer, S.; et al. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study. PLoS ONE 2016, 11, e0155333. [CrossRef]
70. Busk, M.; Mortensen, L.S.; Nordsmark, M.; Overgaard, J.; Jakobsen, S.; Hansen, K.V.; Theil, J.; Kallehauge, J.F.; D’Andrea, F.P.; Steiniche, T.; et al. PET hypoxia imaging with FAZA: Reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. *Eur. J. Nucl. Med. Mol. Imaging* 2013, 40, 186–197. [CrossRef]

71. Busk, M.; Munk, O.L.; Jakobsen, S.; Wang, T.; Skals, M.; Steiniche, T.; Horsman, M.R.; Overgaard, J. Assessing hypoxia in animal tumor models based on pharmacokinetic analysis of dynamic FAZA PET. *Acta Oncol.* 2010, 49, 922–933. [CrossRef]

72. Wang, H.; Galban, S.; Wu, R.; Bowman, B.M.; Witte, A.; Vetter, K.; Galban, C.J.; Ross, B.D.; Cho, K.R.; Rehemtulla, A. Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. *Clin. Cancer Res.* 2013, 19, 158–169. [CrossRef]

73. Cebulla, J.; Huuse, E.M.; Pettersen, K.; van der Veen, A.; Kim, E.; Andersen, S.; Prestvik, W.S.; Bofin, A.M.; Pathak, A.P.; Bjorkoy, G.; et al. MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. *Br. J. Cancer* 2015, 112, 504–513. [CrossRef]

74. Ellingsen, C.; Hompland, T.; Galappathi, K.; Mathiesen, B.; Rofstad, E.K. DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts. *Radiother. Oncol.* 2014, 110, 335–341. [CrossRef]

75. Ellingsen, C.; Walenta, S.; Hompland, T.; Mueller-Klieser, W.; Rofstad, E.K. The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI. *Transl. Oncol.* 2013, 6, 607–617. [CrossRef]

76. Ovrebo, K.M.; Ellingsen, C.; Hompland, T.; Rofstad, E.K. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: A preclinical study of cervical carcinoma and melanoma xenografts. *Acta Oncol.* 2013, 52, 604–611. [CrossRef]

77. Boellaard, R. Standards for PET image acquisition and quantitative data analysis. *J. Nucl. Med.* 2009, 50 (Suppl. 1), 11S–20S. [CrossRef]

78. Veronese, M.; Rizzo, G.; Aboagye, E.O.; Bertoldo, A. Parametric imaging of (1)(8)F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity. *Eur. J. Nucl. Med. Mol. Imaging* 2014, 41, 1781–1792. [CrossRef]

79. Kristian, A.; Holtedahl, J.E.; Torheim, T.; Futsaether, C.; Hernes, E.; Engebraaten, O.; Maelandsmo, G.M.; Malinen, E. Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts. *Mol. Imaging Biol.* 2017, 19, 271–279. [CrossRef]

80. Krohn, K.A.; Link, J.M.; Mason, R.P. Molecular imaging of hypoxia. *J. Nucl. Med.* 2008, 49 (Suppl. 2), 1295–1485. [CrossRef]

81. Parasuraman, S.; Raveendran, R.; Kesavan, R. Blood sample collection in small laboratory animals. *J. Pharmacol. Pharmacother.* 2010, 1, 87–93. [CrossRef]

82. Convert, L.; Lebel, R.; Gascon, S.; Fontaine, R.; Pratte, J.F.; Charette, P.; Aimez, V.; Lecomte, R. Real-Time Microfluidic Blood-Counting System for PET and SPECT Preclinical Pharmacokinetic Studies. *J. Nucl. Med.* 2016, 57, 1460–1466. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).